RNS Number: 6409R Supreme PLC 02 January 2025

2 January 2025

## Supreme plc

("Supreme", the "Company" or the "Group")

## **Block Admission Return**

Supreme (AIM:SUP), a leading manufacturer, supplier, and brand owner of fast-moving consumer products, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements which were announced on 19 January 2023:

| Name of Company                                    | Supreme PLC  |
|--|--|
| Name of Company                                    |  |
| Name of Scheme                                     | Supreme 2018 EMI Scheme                            |
|  | Supreme 2018 Unapproved Scheme                     |
|  | Supreme 2021 CSOP Scheme                           |
|  | Supreme 2021 Unapproved Scheme                     |
|  | Supreme 2021 Shares ave Scheme                     |
| Period of Return (from/to)                         | 1 July 2024 to 31 December 2024                    |
| Number and class of securities not issued at the   | 1,198,943 ordinary shares of £0.10 each ("Ordinary |
| start of the period under the scheme               | Shares"), as follows:                              |
|  | - 521,049 Ordinary Shares under the                |
|  | Supreme 2018 EMI Scheme                            |
|  |  |
|  | - 193,347 Ordinary Shares under the                |
|  | Supreme 2018 Unapproved Scheme                     |
|  | Supreme 2010 onapproved concine                    |
|  | - 181,026 Ordinary Shares under the                |
|  | Supreme 2021 CSOP Scheme                           |
|  | Supreme 2021 CSOF Scheme                           |
|  | - 54,596 Ordinary Shares under the Supreme         |
|  | 2021 Unapproved Scheme                             |
|  | 2021 Onapproved Scheme                             |
|  | 240.035.0  |
|  | - 248,925 Ordinary Shares under the                |
|  | Supreme 2021 Sharesave Scheme                      |
| Number of securities admitted during the period    | 51,818 Ordinary Shares                             |
| Number of securities issued under the scheme       | 51,818 Ordinary Shares, as follows:                |
| during the period                                  | - 30,503 Ordinary Shares under the Supreme         |
| during the period                                  | 2018 EMI Scheme                                    |
|  | 2018 EIVII Scheme                                  |
|  | 24 245 Onding on Chance and and C                  |
|  | - 21,315 Ordinary Shares under the Supreme         |
|  | 2021 Sharesave Scheme                              |
| Balance under the scheme of securities not yet     | 1,147,125 Ordinary Shares                          |
| issued at the end of the period                    | 1,147,123 Ordinary Shares                          |
| ·  | 1.000 507 Ouding out Shares and 20 January 2002    |
| Number and class of shares originally admitted and | 1,989,587 Ordinary Shares on 20 January 2023       |
| the date of admission                              |  |

In compliance with the FCA's Disclosure Guidance and Transparency Rules (the "Rules"), the Company announces that, as at the date of this announcement, it has 116,641,536 Ordinary Shares in issue. The Company does not hold any Ordinary Shares in treasury and all of the Ordinary Shares have equal voting rights.

The figure of 116,641,536 Ordinary Shares represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.

## **Enquiries:**

**Supreme plc**Sandy Chadha, Chief Executive Officer
Suzanne Smith, Chief Finance Officer

via Vigo Consulting

Ben Canning - Corporate Broking

Zeus (Joint Broker) Jordan Warburton / Alex Campbell-Harris - Investment Banking Benjamin Robertson - Corporate Broking

Vigo Consulting (Financial Public Relations)
Jeremy Garcia / Kendall Hill / Anna Stacey
supreme@vigoconsulting.com

+44 (0)20 7390 0230

+44 (0)161 831 1512

## **About Supreme**

Supreme supplies products across six categories; Batteries, Lighting, Vaping, Sports Nutrition and Wellness, Branded Distribution and Soft Drinks. The Company's capabilities span from product development and manufacturing through to its extensive retail distribution network and direct to consumer capabilities. This vertically integrated platform provides an excellent route to market for well-known brands and products.

The Group has over 3,000 active business accounts with retail customers who manage over 10,000 branded retail outlets. Customers include B&M, Home Bargains, Poundland, Tesco, Sainsburys, Morrisons, Amazon, The Range, Costcutter, Asda, Halfords, Iceland, Waitrose, Aldi and HM Prison & Probation Service.

In addition to distributing globally-recognised brands such as Duracell, Energizer and Panasonic, and supplying lighting products exclusively under the Energizer, Eveready, Black & Decker and JCB licences across 45 countries, Supreme has also developed brands in-house, most notably 88Vape, has a growing footprint in Sports Nutrition and Wellness via its principal brands Sci-MX and Battle Bites, and has recently expanded into the soft drinks market with the acquisitions of Clearly Drinks and Typhoo Tea, adding well-known and established brands to its portfolio.

https://investors.supreme.co.uk/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:msc.decom">msc.decom</a> or visit <a href="mailto:www.ms.com">www.ms.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <a href="Privacy Policy">Privacy Policy</a>.

**END** 

BLRFDLFLSELSEDE